MyLife Diabetes Care announced that its transition into an independent company has now been formally completed. In August, Ypsomed announced that it completed the sale of its diabetes care business to TecMed AG. With this sale, the company transitioned MyLife from a business unit into a standalone company. This follows a recent medtech trend, with […]
TecMed
Ypsomed completes sale of diabetes care business to TecMed
Ypsomed announced today that it successfully completed the sale of its diabetes care business to TecMed AG. Burgdorf, Switzerland–based Ypsomed in April announced its plans to sell the business to help focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
Ypsomed to sell diabetes business, insulin delivery tech to TecMed for $517.7M
Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million (CHF 420 million). Burgdorf, Switzerland–based Ypsomed says the sale helps it focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
